SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
REVB

Revelation Biosciences, Inc. (NASDAQ:REVB)

US · Delayed Price · Currency is USD
Healthcare · Biotechnology
$3.50-$0.19 (-5.15%)
 
Market cap
$1.99M
Insider Score
Health Score
Analyst consensus
Listed since
Nov 17, 2020
Market Cap$1.99M-85.3%
Revenue (ttm)$0
Net Income-$12.16M-49.6%
EPS-$37.63+66.1%
Shares Out569.06K
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume9,801
Open$3.71
Previous Close$3.69
Day's Range$3.50 - $3.80
52-Week Range$3.08 - $40.60
Betan/a
AnalystsBuy
Price Targetn/a
Earnings DateApr 1, 2027
-4.88% (1D)
No price history available.

About REVB

Revelation Biosciences, Inc. is a biopharmaceutical firm currently in its clinical development phase, dedicated to the advancement and commercialization of treatments and diagnostic tools targeting the immune system. The company's therapeutic pipeline includes promising candidates such as GEM-AKI, which is being developed as a potential therapy for both the prevention and management of acute kidney injury, and GEM-CKD, intended for the prevention and treatment of chronic kidney disease. Established in 2019, this San Diego, California-based enterprise was formerly known as Petra Acquisition, Inc., before officially adopting the name Revelation Biosciences, Inc. in January 2022.

Address
4660 La Jolla Village Drive, San Diego, CA, 92122, US
Market Cap
2 million
Employees
8
Industrial Classification
Biotechnology
Financial Health Score
Fair
From REVB’s reported statements · Q3 2026 (trailing 12 months) · 4 of 5 pillars

Next catalysts

1 Day
-5.15%
5 Days
-12.50%
1 Month
-4.89%
6 Months
-53.27%
1 Year
-85.29%

$REVB stock is featured in our Insider Trades datasets.

→ All Stock Lists

Recently reported changes in REVB holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by REVB's directors and management

Net Shares Purchased by Insiders−1−102025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

REVB Estimated quarterly lobbying spending

Source: U.S. Senate LDA

U.S. Patents

New REVB patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to REVB from public contracts

Source: USAspending.gov

Bull Case vs Bear Case

AI-generated from REVB’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
No data yet
—
Analyst Ratings
62% of score
99
News & Sentiment
38% of score
72

News check: Multiple concrete announcements of accelerated development plans, strategic partnerships, and positive financial results suggest bullish momentum entering an important period.

Recent Insider Activity

Buys
0
Sells
0
Buy Value
$0
Distinct Buyers
0

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.